Welcome to our dedicated page for SOPHiA GENETICS SA SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity compensation awards and corrected prior ownership data. He received a grant of 82,335 share options with a $5.04 exercise price expiring on April 2, 2036, plus 56,468 RSUs. The Form 4/A updates his beneficial ownership to 148,854 ordinary shares after these awards, amending an earlier filing that understated this amount.
SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards and corrected her reported share holdings. She was granted an option for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. Following these awards and a correction to a prior report, her directly held ordinary shares are reported as 224,248.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported equity compensation grants and a correction to his reported holdings. He received a share option for 164,671 ordinary shares at an exercise price of $5.04 per share and a grant of 112,936 ordinary shares in the form of restricted stock units under the 2021 Equity Incentive Plan. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and expires on April 2, 2036. The amendment corrects his beneficial ownership after the transactions to 650,052 ordinary shares, instead of 112,936 shares previously reported due to an inadvertent error.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported equity awards and a correction to his reported holdings. He received a share option for 119,760 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036, and 82,136 restricted stock units representing future ordinary shares.
The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The amendment also corrects his ordinary share holdings after the reported transactions to 207,949 shares, instead of 82,136 shares previously reported due to an error.
Morgan Stanley Smith Barney LLC filed a Form 144 for SOPH listing 20,689 Restricted Stock Units of Common Stock to be sold on 04/02/2026. The filing also records three 10b5-1 sales by ROSS J MUKEN: 1,183 shares on 03/19/2026 for $5,670.95, and 760 shares on 02/19/2026 and 01/20/2026 for $3,665.94 and $4,077.78, respectively.
Company submitted a Form 144 reporting a proposed sale of 12,354 Restricted Stock Units on 04/02/2026. The filing lists prior Rule 10b5-1 sales by Daan Guido Maria Van Well of 684 shares on three dates in 2026 as examples.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 18,556 shares of common stock. The filing lists the shares as Restricted Stock Units with a reported aggregate figure of $93,522.24 and cites 68,486,338 shares outstanding as of 04/06/2026. The excerpt also lists multiple 10b5-1 sales by Zhenyu Xu between 01/13/2026 and 03/19/2026 (examples shown: 4,000 and 608 share trades with corresponding proceeds).
SOPH submitted a Form 144 notice disclosing a proposed sale of 6,335 shares of Common Stock tied to Restricted Stock Units through Morgan Stanley Smith Barney LLC, dated 04/06/2026. The filing also records prior 10b5-1 sales of 774 shares on 03/19/2026, with a reported value of $3,704.52.
Morgan Stanley Smith Barney LLC reported Form 144 trading activity tied to SOPH restricted stock units and 10b5-1 sales. The filing lists 14,556 shares of restricted stock units dated 04/02/2026 and 5,000 shares dated 08/18/2024, and multiple 10b5-1 sale transactions between 01/12/2026 and 03/19/2026.
The excerpt shows a series of 10b5-1 sales by Philippe Menu: transactions of 5,000 and 608 common shares on several dates with reported proceeds (for example, $22,592.50 on 03/12/2026 and $2,912.81 on 03/19/2026). The filing lists the broker and indicates the trades were executed under an automated plan.
SOPH affiliate filed a Form 144 notice to sell 8,797 shares of Common stock tied to Restricted Stock Units dated 04/02/2026, through Morgan Stanley Smith Barney LLC. The excerpt also lists three prior 10b5-1 sales by Manuela Valente of 380 shares each on 01/20/2026, 02/19/2026, and 03/19/2026 at $2,040.98, $1,833.88, and $1,818.34, respectively.